Análisis opcionales del producto
Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
UnitedHealth Group Incorporated's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $338.3B | |
|---|---|---|
| Revenue (ttm) | 450.1B | |
| Net income (ttm) | 15.9B | |
| EPS (ttm) | $17.5 | |
| Shares out | 897.6M | |
| P/E (trailing) | 23.3x | |
| P/E (forward) | 16.7x | |
| Dividend | $9.28 (2.28%) | |
| Volume | 2,955,783 | |
| Beta | 0.61 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $287.60B | $324.16B | $371.62B | $400.28B | $447.57B | +11.7% |
| Gross profit | $69.65B | $79.62B | $90.96B | $89.40B | $82.92B | +4.5% |
| Operating income | $23.97B | $28.44B | $32.36B | $32.29B | $18.96B | -5.7% |
| Net income | $17.29B | $20.12B | $22.38B | $14.41B | $12.06B | -8.6% |
| EPS (diluted) | $18.08 | $21.18 | $23.86 | $15.51 | $13.23 | -7.5% |
| EBITDA | $27.07B | $31.84B | $36.33B | $28.08B | $23.06B | -3.9% |
| R&D | — | — | — | — | — | — |
| SG&A | $42.58B | $47.78B | $54.63B | $53.01B | $59.59B | +8.8% |
Recent company headlines from major financial publishers.
The Base path represents the modal expectation where UnitedHealthcare maintains its market share and core profitability, while OptumHealth gradually narrows operating losses. Under this progression, operating margins trend toward normalized levels, supporting fair value expansion toward $448.25.
The Bull path requires OptumHealth care delivery margins to recover rapidly, commercial employer enrollment to gain market share, and effective contract repricing to outpace medical inflation. The reader would see confirmation through consecutive quarters of expanding operating margins in care delivery and accelerating earnings per share growth toward $578.10.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 6.0% | $553 | $592 | $643 | $717 | $833 |
| 7.0% | $473 | $494 | $521 | $556 | $603 |
| 8.0% | $420 | $433 | $448 | $468 | $492 |
| 9.0% | $381 | $389 | $399 | $411 | $426 |
| 10.0% | $351 | $357 | $364 | $372 | $381 |
Upcoming earnings date and setup when available.
La calificación que llevaba la edición de análisis publicada cada mes. Una calificación compara el precio en la fecha del análisis con el valor razonable; no es un registro de si la valoración acertó.
| Año | ene | feb | mar | abr | may | jun | jul | ago | sept | oct | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
